Asta Medica, Aktiengesellschaft

Viatris Gmbh & Co Kg

Michael Lobisch

Jurgen Engel

Istvan Szelenyi

Peter Emig

Bernd Nickel

J&uuml;rgen Engel

Ralph Venhaus

Helmut Hettche

Joachim Goede

Klaus Wessel

Harald Borbe

Helmut Momberger

Gabriela Pergande

Jean Schoenen

Manfred Peukert

Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.

Oral forms of administration containing solid flupirtine with controlled release of active substance

The invention relates to the use of racemic &agr;-lipoic acid or its enantiomers or pharmaceutically acceptable salts, amides, esters or thioesters thereof, in reduced or oxidized form, as active ingredient in the prevention or the acute or chronic treatment of migraine.

Treatment of migraine by administration of &agr;-lipoic acid or derivatives thereof

A combination medication containing flupirtin and morphine for the treatment of pain and the prevention of morphine dependence

Combination medication containing flupirtin and morphine for the

Flupirtine is used for the treatment of disorders involving skeletal muscle tension.

Pharmaceutical composition comprising flupirtine and its use to combat

Growing community of inventors

Ober-Ramstadt, Germany

Michael Lobisch